Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Tanya Maria Laidlaw, M.D.

Co-Author

This page shows the publications co-authored by Tanya Laidlaw and Kathleen Buchheit.
Connection Strength

8.214
  1. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021 08; 148(2):574-584.
    View in: PubMed
    Score: 0.968
  2. Influence of daily aspirin therapy on ACE2 expression and function-implications for SARS-CoV-2 and patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2021 07; 51(7):968-971.
    View in: PubMed
    Score: 0.964
  3. The importance of timely diagnosis of aspirin-exacerbated respiratory disease for patient health and safety. World J Otorhinolaryngol Head Neck Surg. 2020 Dec; 6(4):203-206.
    View in: PubMed
    Score: 0.917
  4. Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2020 10; 8(9):3170-3171.
    View in: PubMed
    Score: 0.910
  5. IL-5Ra marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2020 06; 145(6):1574-1584.
    View in: PubMed
    Score: 0.888
  6. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020 04; 124(4):326-332.
    View in: PubMed
    Score: 0.871
  7. Update on the Management of Aspirin-Exacerbated Respiratory Disease. Allergy Asthma Immunol Res. 2016 Jul; 8(4):298-304.
    View in: PubMed
    Score: 0.686
  8. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016 05; 137(5):1566-1576.e5.
    View in: PubMed
    Score: 0.660
  9. Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021 08; 148(2):348-350.
    View in: PubMed
    Score: 0.242
  10. Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Ra in a real-world setting. J Allergy Clin Immunol Pract. 2021 07; 9(7):2910-2912.e1.
    View in: PubMed
    Score: 0.237
  11. Aspirin-Exacerbated Respiratory Disease: Association Between Patient-Reported Sinus and Asthma Morbidity. J Allergy Clin Immunol Pract. 2021 04; 9(4):1604-1611.
    View in: PubMed
    Score: 0.233
  12. A retrospective analysis of bronchiectasis in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2020 09; 8(8):2799-2801.
    View in: PubMed
    Score: 0.223
  13. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. Sci Immunol. 2021 Feb 26; 6(56).
    View in: PubMed
    Score: 0.059
  14. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2021 03; 147(3):827-844.
    View in: PubMed
    Score: 0.058
  15. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020 05 28; 181(5):1016-1035.e19.
    View in: PubMed
    Score: 0.056
  16. Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism. Mucosal Immunol. 2019 05; 12(3):679-690.
    View in: PubMed
    Score: 0.051
  17. A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019 04; 7(4):1338-1340.
    View in: PubMed
    Score: 0.050
  18. Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature. 2018 08; 560(7720):649-654.
    View in: PubMed
    Score: 0.050
  19. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2018 May - Jun; 6(3):1045-1047.
    View in: PubMed
    Score: 0.048
  20. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway. J Immunol. 2015 Oct 15; 195(8):3537-45.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.